Peculiarities of treatment of ovarian dysfunctions in young patients with metabolic syndrome

Abstract

Metabolic syndrome (MS) ranks first in the structure of risk factors for cardiovascular diseases, thus increasing the incidence of myocardial infarction or stroke 2-3 times compared to healthy people. In the Republic of Moldova, MS has an incidence of 36% in the general populations. This study was prompted by the fact that there is limited information in the specialized literature regarding ovarian dysfunctions in patients with MS, with existing data mainly focusing on polycystic ovary syndrome. Objective of the study: Evaluation of the type of ovarian dysfunction and the effectiveness of treatment in young women (19-30 years) with metabolic syndrome. The results of the study demonstrated that ovarian dysfunctions negatively impact the clinical course of MS, increasing the deposition of visceral adipose tissue, while MS also negatively affects reproductive health. Conclusions: Ovarian dysfunctions in young women with MS are predominantly anovulatory, more frequently develop after the pathogenetic mechanism of resistant ovaries and clinically manifested by: opsomenorrhea, opsomenorrhea with oligomenorrhea, opsomenorrhea with hypermenorrhea, spaniomenorrhea and spaniomenorrhea with oligomenorrhea. Ovarian dysfunctions in patients with a BMI > 30 have a direct correlation (r = 0.78; р = 0.01) with high levels of E1 (estrone), T (testosterone) and DHEAs (dehydroepiandrostenedione sulfate). The most effective complex treatment for ovarian dysfunction in young patients with MS was the one administered to patients in group III: combined diet therapy with physical exercise, metformin, and COC preparations (combined contraceptives with natural estrogens and antiandrogens). Medical treatment of ovarian dysfunction in patients with MS is more effective when body mass index(BMI) in the range of ≥ 25 and < 30.